Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03684642 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
A Phase 3 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 3
- Development phase
- 908
- Enrollment target
NCT03684642 is a Phase 3 study that was terminated before completion, run by Sanofi. The registered enrollment target is 908 participants.
The verdict
NCT03684642, a Phase 3 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 908 participants
- Enrollment target
Study Summary
Primary Objective: To demonstrate the non-inferiority of once weekly injection of efpeglenatide in comparison to once weekly injection of dulaglutide on glycated hemoglobin (HbA1c) change in participants with Type 2 diabetes mellitus (T2DM) inadequately controlled with metformin. Secondary Objectives: * To demonstrate the superiority of once weekly injection of efpeglenatide with once weekly injection of dulaglutide on glycemic control. * To demonstrate the superiority of once weekly injection of efpeglenatide with once weekly injection of dulaglutide on body weight. * To evaluate the safety of once weekly injection of efpeglenatide and once weekly injection of dulaglutide.
Interventions
- DRUG Dulaglutide
- DRUG Efpeglenatide
- DRUG Background therapy Metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 908 participants |
| Start Date | 2018-09-26 |
| Est. Completion | 2020-11-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03684642
The ClinicalTrials.gov registry entry for NCT03684642 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 908 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dulaglutide is the first listed.
NCT03684642 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03684642 about?
NCT03684642 is a clinical study titled "Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin". Primary Objective: To demonstrate the non-inferiority of once weekly injection of efpeglenatide in comparison to once weekly injection of dulaglutide on glycated hemoglobin (HbA1c) change in participants with Type 2 diabetes mellitus (T2DM) inadequately controlled with metformin. Secondary Objecti...
What is the current status of trial NCT03684642?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 908 participants. The study started on 2018-09-26. Estimated completion is 2020-11-17.
What interventions are being tested in trial NCT03684642?
The interventions under investigation include: Dulaglutide (DRUG), Efpeglenatide (DRUG), Background therapy Metformin (DRUG).
Who is sponsoring clinical trial NCT03684642?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.